Regent Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Regent Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,375	Closed	-$307K	–	210
2017 Q2	$307K	Hold	3,375	–	–	0.11%	171
2017 Q1	$296K	Hold	3,375	–	–	0.11%	167
2016 Q4	$280K	Sell	3,375 -75	-2%	-$6.45K	0.14%	156
2016 Q3	$319K	Hold	3,450	–	–	0.17%	143
2016 Q2	$268K	Hold	3,450	–	–	0.15%	153
2016 Q1	$285K	Hold	3,450	–	–	0.16%	147
2015 Q4	$361K	Hold	3,450	–	–	0.19%	131
2015 Q3	$363K	Hold	3,450	–	–	0.2%	128
2015 Q2	$472K	Hold	3,450	–	–	0.24%	116
2015 Q1	$430K	Hold	3,450	–	–	0.22%	122
2014 Q4	$312K	Sell	3,450 -150	-4%	-$12.5K	0.16%	146
2014 Q3	$260K	Hold	3,600	–	–	0.13%	159
2014 Q2	$224K	Sell	3,600 -190	-5%	-$11.5K	0.11%	170
2014 Q1	$259K	Buy	3,790 +190	+5%	+$14K	0.14%	158
2013 Q4	$253K	Hold	3,600	–	–	0.14%	151
2013 Q3	$260K	Sell	3,600 -175	-5%	-$11.6K	0.17%	138
2013 Q2	$210K	Buy	+3,775	New	+$235K	0.16%	142

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Regent Investment Management's BMRN Position: Q3 2017 in Review

Regent Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 3,375 shares — an estimated $307K sold.

Regent Investment Management first reported a position in BMRN in Q2 2013 and held it in 17 quarters. The position peaked at $472K in Q2 2015. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

Regent Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Regent Investment Management sold 3,375 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $307K.
Regent Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Regent Investment Management's BioMarin Pharmaceuticals position peaked at $472K in Q2 2015.
411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Regent Investment Management's 13F filing for Q3 2017, filed 12 Oct 2017.